Welcome to our dedicated page for Creative Med Technology Hldgs SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Creative Medical Technology Holdings, Inc.'s SEC filings document governance, capital-structure actions and material events for a clinical-stage regenerative medicine company. Proxy statements cover annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification and stockholder voting tied to Nasdaq share-issuance rules.
Current reports describe warrant exercise inducement agreements, private-placement warrant issuance, registered share issuance under a Form S-3, working-capital use of proceeds and board compensation actions. The filings frame the company's disclosure record around common stock, warrants, shareholder approvals, executive compensation and public-company governance.
Creative Medical Technology Holdings (CELZ) called its 2025 Annual Meeting for December 18, 2025 at 9:00 a.m. PST in Solana Beach, CA. Stockholders will vote on three items: electing five directors, an advisory say‑on‑pay for named executive officers, and ratifying Haynie & Company as independent auditor for the year ending December 31, 2025.
The Board set October 27, 2025 as the record date, with 2,579,930 shares of common stock outstanding on that date. Directors are elected by a plurality of votes cast; the say‑on‑pay and auditor ratification require a majority of shares present and entitled to vote. The Board unanimously recommends FOR all three proposals.
The company reports three independent directors on its five‑member Board and standard committee structures. For 2024, audit fees to Haynie & Company were $92,772. The proxy also outlines executive and director compensation, equity plans, and related‑party policies to guide governance and compliance.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 135,531 shares of Creative Medical Technology Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises voting and investment power over the shares held by the Master Fund, and Mr. Boyd, as managing member, is reported with the same shared voting and dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The Master Fund is identified as the direct holder and retains the right to receive dividends or sale proceeds.
Creative Medical Technology Holdings, Inc. reported cash and short-term investments of $6,544,120 and total assets of $7,105,228 at June 30, 2025, with positive working capital of approximately $6,355,063 and stockholders' equity of $6,827,584. The company remains unprofitable, recording a six-month net loss of $2,871,400 versus $2,599,272 a year earlier.
Commercial revenue was minimal: $0 for the quarter and $3,000 for the six months, down from $8,000 a year ago. Operating loss for the six months was $2,923,998. Research and development expense for the six months totaled $1,244,565 while selling, general and administrative expense was $1,619,914. Basic net loss per share for six months was $(1.26) on a weighted average of 2,282,290 shares.
The company strengthened liquidity through warrant exercises and related financings, generating approximately $3.7 million of net proceeds during the period and reporting 4,147,478 warrants outstanding at June 30, 2025. Clinical programs show material progress: an independent Data Safety Monitoring Board completed a safety review and recommended continuation of the CELZ-201 ADAPT trial after initial cohorts, and the company completed dosing of the second cohort (20 patients total) in Q2 2025.